{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:25:24Z","timestamp":1782051924766,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01210-3","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:24:59Z","timestamp":1719512699000},"page":"2077-2092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04053881","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bernhard","family":"Korge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vanhooteghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Machovcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Perrussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisavet","family":"Lazaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Vidal","family":"Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Duenas","family":"Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Fierens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Heidbrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"1210_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1210_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8: 743180.","journal-title":"Front Med (Lausanne)"},{"key":"1210_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jvc2.170","volume":"2","author":"A Crochard","year":"2023","unstructured":"Crochard A, Gherardi A, Hueber Kollen M, Issa S, Villani A. Assessing the burden of patients with psoriasis through the concept of cumulative life course impairment: a narrative literature review. JEADV Clin Pract. 2023;2:423\u201331.","journal-title":"JEADV Clin Pract"},{"key":"1210_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists\u2019 Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628\u201337.","journal-title":"Br J Dermatol."},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228\u201333.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","volume":"79","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Blauvelt A, Tha\u00e7i D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79:302-14.e6.","journal-title":"J Am Acad Dermatol"},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1111\/jdv.17486","volume":"35","author":"RB Warren","year":"2021","unstructured":"Warren RB, Lebwohl M, Sofen H, et al. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermatol Venereol. 2021;35:2398\u2013408.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.19393","volume":"184","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Warren RB, Gottlieb AB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021;184:652\u201362.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1210_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14712598.2017.1283401","volume":"17","author":"A Campanati","year":"2017","unstructured":"Campanati A, Benfaremo D, Luchetti MM, et al. Certolizumab pegol for the treatment of psoriasis. Expert Opin Biol Ther. 2017;17(3):387\u201394. https:\/\/doi.org\/10.1080\/14712598.2017.1283401.","journal-title":"Expert Opin Biol Ther."},{"key":"1210_CR11","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1111\/jdv.16568","volume":"34","author":"J Seneschal","year":"2020","unstructured":"Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34:2566\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1210_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19296","author":"S Gerdes","year":"2023","unstructured":"Gerdes S, Hoffmann M, Asadullah K, et al. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: week 104 results from the non-interventional, prospective, German multicentre PERSIST study. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19296.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1210_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27\u201333.","journal-title":"Dermatology"},{"key":"1210_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s13555-021-00499-8","volume":"11","author":"M Kojanova","year":"2021","unstructured":"Kojanova M, Cetkovska P, Strosova D, et al. Real-world evidence from more than 1000 patients treated with adalimumab for moderate-to-severe psoriasis in the Czech Republic. Dermatol Ther (Heidelb). 2021;11:543\u201353.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1210_CR15","doi-asserted-by":"publisher","first-page":"2160196","DOI":"10.1080\/09546634.2022.2160196","volume":"34","author":"A Reich","year":"2023","unstructured":"Reich A, Reed C, Schuster C, et al. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016\u20132021. J Dermatolog Treat. 2023;34:2160196.","journal-title":"J Dermatolog Treat"},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jdv.15733","volume":"33","author":"LS van der Schoot","year":"2019","unstructured":"van der Schoot LS, van den Reek JMPA, Groenewoud JMM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33:1913\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1210_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijwd.2019.04.021","volume":"5","author":"AB Gottlieb","year":"2019","unstructured":"Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol. 2019;5:141\u201350.","journal-title":"Int J Womens Dermatol"},{"key":"1210_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107074","volume":"200","author":"Y Ingrasciotta","year":"2024","unstructured":"Ingrasciotta Y, Spini A, L\u2019Abbate L, et al. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: an external validity analysis of 66,639 biologic users from the Italian VALORE project. Pharmacol Res. 2024;200: 107074.","journal-title":"Pharmacol Res"},{"key":"1210_CR19","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris. 2023 (revised January 2024). https:\/\/www.guidelines.edf.one\/\/uploads\/attachments\/clrf2t72k3ttodtjrokdem0cy-0-euroguiderm-pso-gl-draft-2024.pdf. Accessed 15 Jan 2024."},{"key":"1210_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14929","volume":"34","author":"M Turkmen","year":"2021","unstructured":"Turkmen M, Dogan S. Certolizumab pegol in the treatment of psoriasis: real-life data. Dermatol Ther. 2021;34: e14929.","journal-title":"Dermatol Ther"},{"key":"1210_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/12034754221078203","volume":"26","author":"RB Vender","year":"2022","unstructured":"Vender RB, Lynde CW. Certolizumab pegol use in the treatment of moderate-to-severe psoriasis: real-world data from two Canadian centers. J Cutan Med Surg. 2022;26:267\u201373.","journal-title":"J Cutan Med Surg"},{"key":"1210_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13555-022-00861-4","volume":"13","author":"P Gisondi","year":"2023","unstructured":"Gisondi P, Gottlieb AB, Elewski B, et al. Long-term health-related quality of life in patients with plaque psoriasis treated with certolizumab pegol: Three-year results from two randomised phase 3 studies (CIMPASI-1 and CIMPASI-2). Dermatol Ther (Heidelb). 2023;13:315\u201328.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1210_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/09546634.2019.1592096","volume":"31","author":"J Leman","year":"2020","unstructured":"Leman J, Walton S, Layton AM, et al. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J Dermatolog Treat. 2020;31:213\u201321.","journal-title":"J Dermatolog Treat"},{"key":"1210_CR24","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/1346-8138.16128","volume":"48","author":"S Gerdes","year":"2021","unstructured":"Gerdes S, Br\u00e4u B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective German multicenter PERSIST trial. J Dermatol. 2021;48:1854\u201362.","journal-title":"J Dermatol"},{"key":"1210_CR25","first-page":"1","volume":"00","author":"F Verardi","year":"2023","unstructured":"Verardi F, Maul LV, Borsky K, et al. Sex differences in adverse events from systemic treatments for psoriasis: a decade of insights from the Swiss Psoriasis Registry (SDNTT). J Eur Acad Dermatol Venereol. 2023;00:1\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1210_CR26","doi-asserted-by":"publisher","first-page":"adv00354","DOI":"10.2340\/00015555-3711","volume":"101","author":"CP Hern\u00e1ndez-Fern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez-Fern\u00e1ndez CP, Carretero G, Rivera R, et al. Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort. Acta Derm Venereol. 2021;101:adv00354.","journal-title":"Acta Derm Venereol."},{"key":"1210_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.23736\/S0392-0488.20.06748-6","volume":"155","author":"C De Simone","year":"2020","unstructured":"De Simone C, Calabrese L, Balato A, et al. Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. G Ital Dermatol Venereol. 2020;155:434\u201340.","journal-title":"G Ital Dermatol Venereol"},{"key":"1210_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000112","volume":"9","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero A, Constantin MM, Dattola A, et al. Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists. Int J Womens Dermatol. 2023;9: e112.","journal-title":"Int J Womens Dermatol"},{"key":"1210_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","volume":"138","author":"IYK Iskandar","year":"2018","unstructured":"Iskandar IYK, Warren RB, Lunt M, et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138:775\u201384.","journal-title":"J Invest Dermatol"},{"key":"1210_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.14552","volume":"175","author":"J Zweegers","year":"2016","unstructured":"Zweegers J, van den Reek JM, van de Kerkhof PC, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175:340\u20137.","journal-title":"Br J Dermatol"},{"key":"1210_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158:1131\u201341.","journal-title":"JAMA Dermatol"},{"key":"1210_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjd.19314","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Paul C, van de Kerkhof P, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. Br J Dermatol. 2021;184:640\u201351.","journal-title":"Br J Dermatol"},{"key":"1210_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/acr2.11259","volume":"3","author":"VP Bykerk","year":"2021","unstructured":"Bykerk VP, Blauvelt A, Curtis JR, et al. Associations between safety of certolizumab pegol, disease activity, and patient characteristics, including corticosteroid use and body mass index. ACR Open Rheumatol. 2021;3:501\u201311.","journal-title":"ACR Open Rheumatol"},{"key":"1210_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5:e000942.","journal-title":"RMD Open"},{"key":"1210_CR35","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1111\/jdv.16606","volume":"34","author":"A Dattola","year":"2020","unstructured":"Dattola A, Balato A, Megna M, et al. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. J Eur Acad Dermatol Venereol. 2020;34:2839.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s13555-024-01271-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01210-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T11:08:12Z","timestamp":1727521692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01210-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01210-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-024-01271-4","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-024-01271-4","URL":"https:\/\/doi.org\/10.1007\/s13555-024-01271-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bernhard Korge was an advisor to, and\/or received speakers\u2019 honoraria from, and\/or received grants from, and\/or participated in clinical trials from Abbvie, Almirall Hermal, Amgen, Beiersdorf Dermo Medical, Biogen, Bristol Myers Sqibb, Celgene, Dr. Pfleger, Galderma, Janssen-Cilag, Leo Pharma, Lilly, Novartis, Pierre Fabre, UCB Pharma. Charles W Lynde received speaker fees and\/or research grants from and\/or participated in advisory boards of Abbvie, Amgen, Biogen, Eli Lilly, Janssen, Novartis, Sanofi Genzyme UCB Pharma. Alena Machovcova participated in clinical trials and\/or received honoraria as an investigator from, and\/or participated in advisory boards, and\/or received speaker fees from AbbVie, Almirall, Amgen, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi Genzyme and UCB Pharma. Elisavet Lazaridou received speaker fees and research grants from and\/or participated in advisory boards from UCB Pharma. David Vidal Sarro participated in clinical trials and\/or received honoraria as a consultant and\/or investigator, and\/or received speaker fees from AbbVie, Almirall, Janssen, Lilly, Novartis and UCB Pharma. Ines D Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, and Tanja Heidbred are employees of UCB Pharma. Richard B Warren received consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis, and UCB Pharma; and honoraria from Astellas, DiCE, GSK, and Union. Richard B Warren is an Editor-in-Chief of<i> Dermatology and Therapy<\/i>. Richard Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Olivier Vanhooteghem, Marc Perrussel, and Claudio Marasca report no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"CIMREAL was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines and with the Helsinki Declaration of 1975, as revised in 1983. Approval to conduct this study was obtained from the respective ethics committees of all participating centers. The patients in this manuscript have given written informed consent to the publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}